We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI-Powered Tool Combs through Electronic Health Records For Faster Diagnoses of Rare Diseases

By HospiMedica International staff writers
Posted on 05 Jul 2024

A rare disease is defined as one that affects fewer than 200,000 individuals. More...

Collectively, over 10,000 known rare diseases impact more than 30 million people. While some of these diseases, like multiple sclerosis, are well-recognized, most—including bartonellosis, maple syrup urine disease, and visual snow syndrome—are not. Acute hepatic porphyria (AHP), a group of rare genetic disorders, affects 1 in 100,000 people, predominantly women. The symptoms often correlate with the menstrual cycle and can lead to severe, even life-threatening, episodes characterized by abdominal pain, nausea, vomiting, limb weakness, and anxiety. In 2019, the FDA approved givosiran as a prophylactic treatment for these recurrent attacks. However, the average time to diagnose AHP is 15 years, largely because physicians encounter it so infrequently. During this diagnostic delay, the disease can worsen and cause irreversible harm. Now, researchers have created an artificial intelligence (AI) tool that can identify potential patients with AHP, thus aiding in the diagnosis and management of this rare genetic disease.

This predictive algorithm developed by the team at UCLA Health (Los Angeles, CA, USA) under Project Zebra, sifts through electronic health records to spot patterns indicative of disease, alerting physicians to patients who may need further testing and diagnosis. It specifically targets suspected porphyria patients and was trained on a dataset that included de-identified patient records from UCSF and UCLA—part of approximately 10 million records throughout the UC system. The algorithm's development was complicated by the often lengthy approval process required for accessing patient data, and the fact that algorithms improve with access to vast datasets from various institutions, though obtaining the necessary permissions can be challenging. To overcome this, zebraMD has implemented Virtual Pooling, a patented technology that allows the algorithm to learn from data without actually transferring it.

One of the main hurdles in developing the algorithm was the unorganized nature of patient data, which includes both structured data, like vital signs and lab results, and unstructured data, such as physician's notes. The latter presents particular difficulties for algorithms, which prompted the researchers to refine and structure the data. The researchers equipped the model with detailed symptom information and references to a rare and genetic disease database maintained by the National Institutes of Health, which catalogs signs, symptoms, and clinical presentation of diseases including porphyria. The algorithm was then allowed to independently scan through the data and identify patterns, an approach that is crucial given the high rate of misdiagnosis associated with rare diseases. According to findings published in the Journal of the American Medical Informatics Association, the algorithm accurately predicted referrals for AHP testing with an accuracy between 89% and 93%, and it identified 71% of the patients who tested positive for the disease earlier than they were actually diagnosed, saving an average of 1.2 years per case. Currently, Project Zebra is expanding its focus to include predicting cerebral aneurysms, a potentially life-threatening condition characterized by the expansion of a weakened blood vessel in the brain.

“I hope that at some point this is a standard feature of any electronic health records system,” said Katharina “Kat” Schmolly, MD, a UCLA medical student who co-created the algorithm. “The more patients we can diagnose, the more we can monitor over time. That means we can learn what works and what doesn't work. We can create precision medicine approaches for these rare diseases. Many of them don't have any treatments yet. So hopefully, we can find new treatment options for them.”

Related Links:
UCLA Health


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
12-Channel ECG
CM1200B
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.